financetom
Business
financetom
/
Business
/
India's Infosys accuses rival Cognizant of anti-competitive practices
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
India's Infosys accuses rival Cognizant of anti-competitive practices
Jan 10, 2025 6:15 AM

BENGALURU (Reuters) - India's Infosys filed a counterclaim against rival Cognizant in a Texas federal court on Thursday, accusing the U.S.-based firm of engaging in anti-competitive practices and poaching key executives.

India's second-largest software company accused Cognizant of anti-competitive practices such as including clauses in contracts that stop clients from awarding IT services work to competitors and refusing them training on its software.

The Bengaluru-based company also said Cognizant indulged in targeted recruitment of key senior executives, including appointing S Ravi Kumar as its CEO in 2023, that delayed its ability to develop a competing software product called Infosys Helix.

Infosys and Cognizant did not immediately respond to Reuters' requests for comments.

The counterclaim comes after Cognizant subsidiary TriZetto (AXPAST.UL) sued Infosys last August, accusing the Indian tech major of stealing trade secrets related to its healthcare insurance software.

TriZetto's Facets and QNXT are used by healthcare insurance companies to automate administrative tasks.

In its complaint the Teaneck, New Jersey-based company said Infosys misused TriZetto's software to create "Test Cases for Facets," which improperly repackaged TriZetto's data into an Infosys product.

Infosys has sought three times its damages suffered as well as the awarding of attorney fees and costs related to the case. The quantum of damages was not disclosed in the filing.

The case is Cognizant TriZetto Software Group Inc v. Infosys Ltd, U.S. District Court for the Northern District of Texas, No. 3:24-cv-02158-X.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Newmont Reduces Workforce by 16% Following Acquisition of Newcrest
Market Chatter: Newmont Reduces Workforce by 16% Following Acquisition of Newcrest
Nov 7, 2025
09:27 AM EST, 11/07/2025 (MT Newswires) -- Newmont ( NEM ) has cut about 16% of its workforce as part of a restructuring following the acquisition of Australian miner Newcrest, Reuters reported Friday, citing an internal memo. In the final stage of the cost and productivity plan, Newmont ( NEM ) cut jobs by roughly 12% at Level of Work...
DalFort Capital Partners Completes Second Add-On Acquisition for the Polymer Adhesives Platform
DalFort Capital Partners Completes Second Add-On Acquisition for the Polymer Adhesives Platform
Nov 7, 2025
DALLAS, Nov. 7, 2025 /PRNewswire/ -- Polymer Adhesives Holdings, LLC (Polymer Adhesives), a portfolio company of DalFort Capital Partners, has acquired Fielco Adhesives (Fielco), a Huntingdon Valley, PA-based manufacturer of industrial epoxy adhesive solutions. Fielco's products serve a broad array of applications, including abrasive converting, industrial brushes, paint rollers, grinding wheels, and electronic encapsulation, among others. The combination of Polymer...
Auna Closes $765 Million Debt Refinancing
Auna Closes $765 Million Debt Refinancing
Nov 7, 2025
09:25 AM EST, 11/07/2025 (MT Newswires) -- Auna ( AUNA ) said Friday that it had completed a $765 million debt refinancing to extend maturities, cut interest expenses, and support cash flow for future growth. Auna ( AUNA ) and its co-issuer Oncosalud jointly issued $365 million in 8.75% senior secured notes due 2032, as well as a $400 million...
Atea Pharmaceuticals Reports Data Supporting Bemnifosbuvir, Ruzasvir Combination to Treat Hepatitis C
Atea Pharmaceuticals Reports Data Supporting Bemnifosbuvir, Ruzasvir Combination to Treat Hepatitis C
Nov 7, 2025
09:00 AM EST, 11/07/2025 (MT Newswires) -- Atea Pharmaceuticals ( AVIR ) said Friday that new modelling data support the fixed-dose combination of bemnifosbuvir and ruzasvir to treat Hepatitis C. The company said the combination reached near-complete inhibition of viral replication and assembly, and secretion into the bloodstream, with a time to cure of approximately seven to eight weeks. The...
Copyright 2023-2026 - www.financetom.com All Rights Reserved